A single arm phase II study to individualize dasatinib dosing based on trough levels and molecular response to maintain efficacy whilst minimising toxicity

DOI number 10.58109/kbsh-1f21
Publisher Australasian Leukaemia and Lymphoma Group (ALLG)
Creator(s)

Australasian Leukaemia and Lymphoma Group (ALLG)

David Yeung (Institute of Medical and Veterinary Science)
Date Made Available 2023
Dataset Individual participant data (IPD) in aggregate form
Description of Dataset

Dataset includes

  • Data for 80 patients over 60 with newly diagnosed CML, using desatinib and monitoring lung function
  • Diagnostic data
  • Treatment data
  • Outcome data
  • Cancer Australia demographic data
    -Year of birth
    -Aboriginal or Torres Strait Islander status (or Ethnicity)
Funding

Australasian Leukaemia and Lymphoma Group (ALLG)
Subject (ANZSRC Category)

Cancer therapy (excl. chemotherapy and radiation therapy)

Molecular targets
ANZCTR Reference ACTRN12616000738426
Publication(s)
Dataset Access

Access can be requested via the Health Data Australia catalogue. Search for the ACTRN number in the catalogue to find datasets associated with this trial or email enquiries to info@allg.org.au
Memberships
Participate in a Trial
Memberships
Clinical Trials & Research
CML11
CMLALL01